Profile

None provided

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition. Hardeman KN, Peng C, Paudel BB, Meyer CT, Luong T, Tyson DR, Young JD, Quaranta V, Fessel JP (2017) Sci Rep : 42604
    › Primary publication · 28205616 (PubMed) · PMC5311997 (PubMed Central)
  2. Shared gene expression patterns in mesenchymal progenitors derived from lung and epidermis in pulmonary arterial hypertension: identifying key pathways in pulmonary vascular disease. Gaskill C, Marriott S, Pratap S, Menon S, Hedges LK, Fessel JP, Kropski JA, Ames D, Wheeler L, Loyd JE, Hemnes AR, Roop DR, Klemm DJ, Austin ED, Majka SM (2016) Pulm Circ 6(4): 483-497
    › Primary publication · 28090290 (PubMed) · PMC5210051 (PubMed Central)
  3. Mitochondrial Haplogroups as a Risk Factor for Herpes Zoster. Levinson RT, Hulgan T, Kalams SA, Fessel JP, Samuels DC (2016) Open Forum Infect Dis 3(4): ofw184
    › Primary publication · 27807590 (PubMed) · PMC5088697 (PubMed Central)
  4. Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension. Bertero T, Oldham WM, Cottrill KA, Pisano S, Vanderpool RR, Yu Q, Zhao J, Tai Y, Tang Y, Zhang YY, Rehman S, Sugahara M, Qi Z, Gorcsan J, Vargas SO, Saggar R, Saggar R, Wallace WD, Ross DJ, Haley KJ, Waxman AB, Parikh VN, De Marco T, Hsue PY, Morris A, Simon MA, Norris KA, Gaggioli C, Loscalzo J, Fessel J, Chan SY (2016) J Clin Invest 126(9): 3313-35
    › Primary publication · 27548520 (PubMed) · PMC5004943 (PubMed Central)
  5. Scavengers of reactive γ-ketoaldehydes extend Caenorhabditis elegans lifespan and healthspan through protein-level interactions with SIR-2.1 and ETS-7. Nguyen TT, Caito SW, Zackert WE, West JD, Zhu S, Aschner M, Fessel JP, Roberts LJ (2016) Aging (Albany NY) 8(8): 1759-80
    › Primary publication · 27514077 (PubMed) · PMC5032694 (PubMed Central)
  6. Fatty Acid Metabolic Defects and Right Ventricular Lipotoxicity in Human Pulmonary Arterial Hypertension. Brittain EL, Talati M, Fessel JP, Zhu H, Penner N, Calcutt MW, West JD, Funke M, Lewis GD, Gerszten RE, Hamid R, Pugh ME, Austin ED, Newman JH, Hemnes AR (2016) Circulation 133(20): 1936-44
    › Primary publication · 27006481 (PubMed) · PMC4870107 (PubMed Central)
  7. Estrogen Metabolite 16α-Hydroxyestrone Exacerbates Bone Morphogenetic Protein Receptor Type II-Associated Pulmonary Arterial Hypertension Through MicroRNA-29-Mediated Modulation of Cellular Metabolism. Chen X, Talati M, Fessel JP, Hemnes AR, Gladson S, French J, Shay S, Trammell A, Phillips JA, Hamid R, Cogan JD, Dawson EP, Womble KE, Hedges LK, Martinez EG, Wheeler LA, Loyd JE, Majka SJ, West J, Austin ED (2016) Circulation 133(1): 82-97
    › Primary publication · 26487756 (PubMed) · PMC4698046 (PubMed Central)
  8. LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells. Whang YM, Park SI, Trenary IA, Egnatchik RA, Fessel JP, Kaufman JM, Carbone DP, Young JD (2016) Oncogene 35(7): 856-66
    › Primary publication · 26119936 (PubMed) · PMC4486321 (PubMed Central)
  9. Identification of a common Wnt-associated genetic signature across multiple cell types in pulmonary arterial hypertension. West JD, Austin ED, Gaskill C, Marriott S, Baskir R, Bilousova G, Jean JC, Hemnes AR, Menon S, Bloodworth NC, Fessel JP, Kropski JA, Irwin D, Ware LB, Wheeler L, Hong CC, Meyrick B, Loyd JE, Bowman AB, Ess KC, Klemm DJ, Young PP, Merryman WD, Kotton D, Majka SM (2014) Am J Physiol Cell Physiol 307(5): C415-30
    › Primary publication · 24871858 (PubMed) · PMC4154073 (PubMed Central)
  10. Rescuing the BMPR2 signaling axis in pulmonary arterial hypertension. West J, Austin E, Fessel JP, Loyd J, Hamid R (2014) Drug Discov Today 19(8): 1241-5
    › Primary publication · 24794464 (PubMed) · PMC4396626 (PubMed Central)
  11. Interaction between bone morphogenetic protein receptor type 2 and estrogenic compounds in pulmonary arterial hypertension. Fessel JP, Chen X, Frump A, Gladson S, Blackwell T, Kang C, Johnson J, Loyd JE, Hemnes A, Austin E, West J (2013) Pulm Circ 3(3): 564-77
    › Primary publication · 24618541 (PubMed) · PMC4070799 (PubMed Central)
  12. Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension. Hemnes AR, Brittain EL, Trammell AW, Fessel JP, Austin ED, Penner N, Maynard KB, Gleaves L, Talati M, Absi T, Disalvo T, West J (2014) Am J Respir Crit Care Med 189(3): 325-34
    › Primary publication · 24274756 (PubMed) · PMC3977729 (PubMed Central)
  13. Author's Reply. Das M, Fessel J, West J (2013) Pulm Circ 3(2): 447-8
    › Primary publication · 24015350 (PubMed) · PMC3757845 (PubMed Central)
  14. Multi-organ abnormalities and mTORC1 activation in zebrafish model of multiple acyl-CoA dehydrogenase deficiency. Kim SH, Scott SA, Bennett MJ, Carson RP, Fessel J, Brown HA, Ess KC (2013) PLoS Genet 9(6): e1003563
    › Primary publication · 23785301 (PubMed) · PMC3681725 (PubMed Central)
  15. Hyperoxia synergizes with mutant bone morphogenic protein receptor 2 to cause metabolic stress, oxidant injury, and pulmonary hypertension. Fessel JP, Flynn CR, Robinson LJ, Penner NL, Gladson S, Kang CJ, Wasserman DH, Hemnes AR, West JD (2013) Am J Respir Cell Mol Biol 49(5): 778-87
    › Primary publication · 23742019 (PubMed) · PMC3931097 (PubMed Central)
  16. Dysfunctional resident lung mesenchymal stem cells contribute to pulmonary microvascular remodeling. Chow K, Fessel JP, Kaoriihida-Stansbury , Schmidt EP, Gaskill C, Alvarez D, Graham B, Harrison DG, Wagner DH, Nozik-Grayck E, West JD, Klemm DJ, Majka SM (2013) Pulm Circ 3(1): 31-49
    › Primary publication · 23662173 (PubMed) · PMC3641738 (PubMed Central)
  17. A process-based review of mouse models of pulmonary hypertension. Das M, Fessel J, Tang H, West J (2012) Pulm Circ 2(4): 415-33
    › Primary publication · 23372926 (PubMed) · PMC3555412 (PubMed Central)
  18. A potential role for insulin resistance in experimental pulmonary hypertension. West J, Niswender KD, Johnson JA, Pugh ME, Gleaves L, Fessel JP, Hemnes AR (2013) Eur Respir J 41(4): 861-71
    › Primary publication · 22936709 (PubMed) · PMC3746982 (PubMed Central)
  19. Metabolomic analysis of bone morphogenetic protein receptor type 2 mutations in human pulmonary endothelium reveals widespread metabolic reprogramming. Fessel JP, Hamid R, Wittmann BM, Robinson LJ, Blackwell T, Tada Y, Tanabe N, Tatsumi K, Hemnes AR, West JD (2012) Pulm Circ 2(2): 201-13
    › Primary publication · 22837861 (PubMed) · PMC3401874 (PubMed Central)
  20. Outcomes in elderly intensive care unit patients, pulmonary hypertension in sickle cell disease, and total liquid ventilation for therapeutic hypothermia after cardiac arrest in rabbits. Brummel NE, Pugh ME, Fessel JP (2012) Am J Respir Crit Care Med 185(4): 453-4
    › Primary publication · 22336678 (PubMed) · PMC3297099 (PubMed Central)
  21. Connectivity map analysis of nonsense-mediated decay-positive BMPR2-related hereditary pulmonary arterial hypertension provides insights into disease penetrance. Flynn C, Zheng S, Yan L, Hedges L, Womack B, Fessel J, Cogan J, Austin E, Loyd J, West J, Zhao Z, Hamid R (2012) Am J Respir Cell Mol Biol 47(1): 20-7
    › Primary publication · 22312021 (PubMed) · PMC3402799 (PubMed Central)
  22. Dysautonomia: perioperative implications. Mustafa HI, Fessel JP, Barwise J, Shannon JR, Raj SR, Diedrich A, Biaggioni I, Robertson D (2012) Anesthesiology 116(1): 205-15
    › Primary publication · 22143168 (PubMed) · PMC3296831 (PubMed Central)
  23. The genetics of pulmonary arterial hypertension in the post-BMPR2 era. Fessel JP, Loyd JE, Austin ED (2011) Pulm Circ 1(3): 305-19
    › Primary publication · 22140620 (PubMed) · PMC3224422 (PubMed Central)
  24. Oxidative injury is a common consequence of BMPR2 mutations. Lane KL, Talati M, Austin E, Hemnes AR, Johnson JA, Fessel JP, Blackwell T, Mernaugh RL, Robinson L, Fike C, Roberts LJ, West J (2011) Pulm Circ 1(1): 72-83
    › Primary publication · 21904662 (PubMed) · PMC3167174 (PubMed Central)
  25. Plasma biomarkers of oxidant stress and development of organ failure in severe sepsis. Ware LB, Fessel JP, May AK, Roberts LJ (2011) Shock 36(1): 12-7
    › Primary publication · 21372753 (PubMed) · PMC3117035 (PubMed Central)
  26. Microarray studies in pulmonary arterial hypertension. Menon S, Fessel J, West J (2011) Int J Clin Pract Suppl (169): 19-28
    › Primary publication · 21176012 (PubMed)
  27. Oxygen therapy-use and abuse. Jackson Roberts L, Fessel J, Arendash G (2010) Clin Cardiol 33(1): 52
    › Primary publication · 20063293 (PubMed)
  28. Seizure-induced formation of isofurans: novel products of lipid peroxidation whose formation is positively modulated by oxygen tension. Patel M, Liang LP, Hou H, Williams BB, Kmiec M, Swartz HM, Fessel JP, Roberts LJ (2008) J Neurochem 104(1): 264-70
    › Primary publication · 17953661 (PubMed)
  29. Orthostatic hypertension: when pressor reflexes overcompensate. Fessel J, Robertson D (2006) Nat Clin Pract Nephrol 2(8): 424-31
    › Primary publication · 16932477 (PubMed)
  30. Oxidative mediated lipid peroxidation recapitulates proarrhythmic effects on cardiac sodium channels. Fukuda K, Davies SS, Nakajima T, Ong BH, Kupershmidt S, Fessel J, Amarnath V, Anderson ME, Boyden PA, Viswanathan PC, Roberts LJ, Balser JR (2005) Circ Res 97(12): 1262-9
    › Primary publication · 16284182 (PubMed)
  31. The biochemistry of the isoprostane, neuroprostane, and isofuran Pathways of lipid peroxidation. Roberts LJ, Fessel JP, Davies SS (2005) Brain Pathol 15(2): 143-8
    › Primary publication · 15912887 (PubMed)
  32. Degree of heteroplasmy reflects oxidant damage in a large family with the mitochondrial DNA A8344G mutation. Canter JA, Eshaghian A, Fessel J, Summar ML, Roberts LJ, Morrow JD, Sligh JE, Haines JL (2005) Free Radic Biol Med 38(5): 678-83
    › Primary publication · 15683723 (PubMed)
  33. Isofurans: novel products of lipid peroxidation that define the occurrence of oxidant injury in settings of elevated oxygen tension. Fessel JP, Jackson Roberts L (2005) Antioxid Redox Signal 7(1-2): 202-9
    › Primary publication · 15650408 (PubMed)
  34. A nomenclature system for isofurans. Taber DF, Fessel JP, Roberts LJ (2004) Prostaglandins Other Lipid Mediat 73(1-2): 47-50
    › Primary publication · 15165030 (PubMed)
  35. Localization of isoketal adducts in vivo using a single-chain antibody. Davies SS, Talati M, Wang X, Mernaugh RL, Amarnath V, Fessel J, Meyrick BO, Sheller J, Roberts LJ (2004) Free Radic Biol Med 36(9): 1163-74
    › Primary publication · 15082070 (PubMed)
  36. The biochemistry of the isoprostane, neuroprostane, and isofuran pathways of lipid peroxidation. Roberts LJ, Fessel JP (2004) Chem Phys Lipids 128(1-2): 173-86
    › Primary publication · 15037162 (PubMed)
  37. Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Montine KS, Quinn JF, Zhang J, Fessel JP, Roberts LJ, Morrow JD, Montine TJ (2004) Chem Phys Lipids 128(1-2): 117-24
    › Primary publication · 15037157 (PubMed)
  38. Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease. Fessel JP, Hulette C, Powell S, Roberts LJ, Zhang J (2003) J Neurochem 85(3): 645-50
    › Primary publication · 12694390 (PubMed)
  39. Discovery of lipid peroxidation products formed in vivo with a substituted tetrahydrofuran ring (isofurans) that are favored by increased oxygen tension. Fessel JP, Porter NA, Moore KP, Sheller JR, Roberts LJ (2002) Proc Natl Acad Sci U S A 99(26): 16713-8
    › Primary publication · 12482927 (PubMed) · PMC139209 (PubMed Central)